For those living in the shadow of mental health conditions such as PTSD, anxiety, and depression, finding a way forward can sometimes feel impossible – especially when conventional treatments have offered little succor. Psilocybin, a psychoactive chemical found in some mushrooms, spent decades being demonized as an illicit drug.But now, results from the first state-regulated psilocybin program in the US suggest the drug could offer a glimmer of hope beyond the confines of clinical trials.Between November 2024 and June 2026, a team led by Oregon Health & Science University tracked 346 clients participating in the program – and found that, in the first three months after taking psilocybin, participants reported significant improvements in mental health, well-being, and life satisfaction.Just one month after the dose, 92.2 percent of participants said the experience had been beneficial, while, on average, their mental health symptoms had fallen dramatically."This paper is going to be cited for decades," says neuroscientist Adrianne R. Wilson-Poe of the Legacy Research Institute and co-director of the Open Psychedelic Evaluation Nexus (OPEN)."This is the first large-scale study to monitor the safety and mental health symptoms of real people in the real world."